Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
VEGFA 7422 BEVACIZUMAB CHEMBL1201583 inhibitor, antibody TALC, MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 11752352, 15705858
VEGFA 7422 GENTAMICIN CHEMBL3039597 NCI 14986132
VEGFA 7422 BEVASIRANIB CHEMBL2110581 TdgClinicalTrial
VEGFA 7422 CELECOXIB CHEMBL118 PharmGKB
VEGFA 7422 SEMAXANIB CHEMBL276711 inhibitor TTD
VEGFA 7422 SORAFENIB TOSYLATE CHEMBL1200485 inhibitor MyCancerGenomeClinicalTrial
VEGFA 7422 LENALIDOMIDE CHEMBL848 ClearityFoundationClinicalTrial
VEGFA 7422 SORAFENIB CHEMBL1336 CGI
VEGFA 7422 DALTEPARIN SODIUM CHEMBL1201460 inhibitor DrugBank 16041398, 17692905, 21091776
VEGFA 7422 CILOSTAZOL CHEMBL799 NCI 11524048
VEGFA 7422 BROLUCIZUMAB CHEMBL3707357 inhibitor ChemblInteractions
VEGFA 7422 TROMETHAMINE CHEMBL1200391 DrugBank 17139284, 17016423, 10592235
VEGFA 7422 VANDETANIB CHEMBL24828 inhibitor DrugBank
VEGFA 7422 FENOFIBRATE CHEMBL672 NCI 11356390
VEGFA 7422 PHENYTOIN CHEMBL16 NCI 15458527
VEGFA 7422 CONBERCEPT CHEMBL2108313 inhibitor ChemblInteractions
VEGFA 7422 PEGAPTANIB SODIUM CHEMBL1201421 antagonist ChemblInteractions
VEGFA 7422 TAK-593 CHEMBL2180604 inhibitor TTD
VEGFA 7422 PEGAPTANIB OCTASODIUM CHEMBL2108752 TdgClinicalTrial, TTD
VEGFA 7422 MUPARFOSTAT (CHEMBL1615835) CHEMBL1615835 inhibitor ChemblInteractions
VEGFA 7422 GLICLAZIDE CHEMBL427216 DrugBank 17602961, 12126787, 14746574, 17046555
VEGFA 7422 CARVEDILOL CHEMBL723 other DrugBank 15071347, 15732037, 15942707, 11378004
VEGFA 7422 RANIBIZUMAB CHEMBL1201825 inhibitor TdgClinicalTrial, ChemblInteractions, TEND, DrugBank 17046701, 18035187, 19668384, 15973626, 17049020, 17031284, 15671306, 18046235, 16935211, 18054637
VEGFA 7422 PYROGLUTAMIC ACID CHEMBL397976 DrugBank 17139284, 17016423, 10592235
VEGFA 7422 CHEMBL262489 CHEMBL262489 DrugBank
VEGFA 7422 BEVASIRANIB SODIUM CHEMBL2103797 inhibitor TTD
VEGFA 7422 BEVACIZUMAB 111IN CHEMBL3707253 ChemblInteractions
VEGFA 7422 LITHOCHOLIC ACID CHEMBL1478 inhibitor TTD
VEGFA 7422 CHEMBL313417 CHEMBL313417 inhibitor TTD
VEGFA 7422 JUGLONE CHEMBL43612 inhibitor TTD
VEGFA 7422 AFLIBERCEPT CHEMBL1742982 inhibitor, binder, antibody TALC, MyCancerGenome, TdgClinicalTrial, ChemblInteractions, DrugBank, TTD 22813448
VEGFA 7422 PENTOSAN POLYSULFATE SODIUM CHEMBL1201516 NCI 17071199
VEGFA 7422 CHEMBL88153 CHEMBL88153 NCI 14717786

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
VEGFA rs144854329 del/del cetuximab efficacy yes variant is described as "-2549D/I (deletion/insertion of 18pb) (rs35569394)". Genotype del/del is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes GGTCCCACTCTTCCCACA/GGTCCCACTCTTCCCACA + GGTCCCACTCTTCCCACA/del. 26615857 1451159544
VEGFA rs3025039 CT + TT salbutamol PD yes as measured by change in FEV1. Genotypes CT + TT is associated with decreased response to salbutamol in children with Asthma as compared to genotype CC. 31486735 1450932911
VEGFA rs1570360 GG cetuximab efficacy yes Genotype GG is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes AA + AG. 26615857 1447674849
VEGFA rs9369421 CC + CT carboplatin efficacy yes Response refers to survival time. Please note, alleles have been complemented to the + chromosomal strand. Genotypes CC + CT are associated with increased response to carboplatin and taxanes in women with as compared to genotype TT. 26194361 1446897254
VEGFA rs1570360 AA + AG ranibizumab efficacy no Genotype was not statistically significantly associated with treatment response. Response was measured by difference of best corrected visual acuity (ETDRS letters) pre- and post- treatment. Power calculations showed that the sample size was not large enough to have enough statistical power for this SNP. Genotypes AA + AG are not associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype GG. 23570466 982025950
VEGFA rs833069 TT bevacizumab efficacy no as determined by changes in visual acuity score. Please note; alleles were reported as A and G, here we represent these by T and C, respectively. [stat_test: anova, followed by permutation testing for corrected probabilities] Genotype TT is not associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype CC. 22594510 827920061
VEGFA rs3025039 CC bevacizumab efficacy no as determined by changes in visual acuity score. [stat_test: anova, followed by permutation testing for corrected probabilities] Genotype CC is not associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype TT. 22594510 827920081
VEGFA rs833069 CT ranibizumab efficacy no Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections. Genotype CT is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype CC. 22840423 981755292
VEGFA rs833069 TT ranibizumab efficacy no Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections. Genotype TT is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype CC. 22840423 981755270
VEGFA rs10434 AA + AG cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes AA + AG are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype GG. 24090479 1183700949
VEGFA rs2010963 CC cyclophosphamide efficacy no No significant difference genotype frequencies were seen between patients who were responders to chemotherapy, and those who were non-responders. Patients with advanced prostate cancer undergoing metronomic chemotherapy. Responders were classified as patients who had a decrease in prostrate-specific antigen (PSA) of >= 50% and a PSA stabilization of >= 6 months. Patients also received celecoxib and dexamethasone, and some patients received docetaxel-, mitoxantrone-, and vinorelbine-based chemotherapeutic regimens. Genotype CC is not associated with response to cyclophosphamide in people with Prostatic Neoplasms as compared to genotypes CG + GG. 23860526 1183699164
VEGFA rs7664413 CT + TT cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes CT + TT are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CC. 24090479 1183700979
VEGFA rs699947 CC cyclophosphamide efficacy no Not significant by Bonferroni's correction (p-value set at <0.017). Patients with advanced prostate cancer undergoing metronomic chemotherapy who have the CC genotype were more frequently non-responders to chemotherapy. Responders were classified as patients who had a decrease in prostrate-specific antigen (PSA) of >= 50% and a PSA stabilization of >= 6 months. Patients also received celecoxib and dexamethasone, and some patients received docetaxel-, mitoxantrone-, and vinorelbine-based chemotherapeutic regimens. Genotype CC is not associated with decreased response to cyclophosphamide in people with Prostatic Neoplasms as compared to genotypes AA + AC. 23860526 1183699124
VEGFA rs833068 A bevacizumab efficacy no Allele A is not associated with response to bevacizumab in women with Breast Neoplasms as compared to allele G. 28045923 1448995829
VEGFA rs3025039 TT cyclophosphamide efficacy no No significant difference genotype frequencies were seen between patients who were responders to chemotherapy, and those who were non-responders. Patients with advanced prostate cancer undergoing metronomic chemotherapy. Responders were classified as patients who had a decrease in prostrate-specific antigen (PSA) of >= 50% and a PSA stabilization of >= 6 months. Patients also received celecoxib and dexamethasone, and some patients received docetaxel-, mitoxantrone-, and vinorelbine-based chemotherapeutic regimens. Genotype TT is not associated with response to cyclophosphamide in people with Prostatic Neoplasms as compared to genotypes CC + CT. 23860526 1183699169
VEGFA rs3025033 AA bevacizumab efficacy no No significant difference in genotype frequencies was seen between patients classified as non-responders, and those classified as responders or partial responders. Responder status was determined by optical coherence tomography; please refer to the paper directly for definitions of responder, partial responder, and non-responder. Genotype AA is not associated with response to bevacizumab in people with Macular Degeneration as compared to genotypes AG + GG. 23584701 1184166166
VEGFA rs833061 C ranibizumab efficacy no Patients underwent 5 monthly injections. Good response at month 5 was defined as best-corrected visual acuity improvement of >= 8 Early Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline. Bonferroni correction for multiple testing. Note that the uncorrected p-value was significant for this allele (p=0.0086), where patients with the CC genotype had a increased chance at a good response, as compared to those with the CT or TT genotype. Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T. 23842101 1184510442
VEGFA rs3025039 C ranibizumab efficacy no Patients underwent 5 monthly injections. Good response at month 5 was defined as best-corrected visual acuity improvement of >= 8 Early Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline. Bonferroni correction for multiple testing. Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T. 23842101 1184510430
VEGFA rs1570360 GG docetaxel efficacy yes The GG genotype was found to be more frequent in non-responders (42.9%) than in patients responding to treatment (0%; complete or partial response). Genotype GG is associated with decreased response to docetaxel in women with Breast Neoplasms as compared to genotypes AA + AG. 24061601 1184512158
VEGFA rs1570360 A imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G. 30713339 1450933529
VEGFA rs2010963 G bevacizumab efficacy no Response was determined by RECIST criteria. In a subgroup analysis excluding the use of anti-angiogenic agents (e.g. bevacuzimab) no significant association was found for any genotypes and response to chemotherapy. Allele G is not associated with response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele C. 25955730 1444842399
VEGFA rs3025039 TT bevacizumab efficacy yes Response to treatment was determined by RECIST criteria. Genotype TT is associated with decreased response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT. 25955730 1444842369
VEGFA rs3025030 C anthracyclines and related substances efficacy no Patients were women with HER2- breast cancer. SNPs in genes in the VEGF pathway were selected to be genotyped (170 plus 16 that were previously investigated for association with response to bevacizumab) and compared between women who received bevacizumab and women who did not. The response was "pathological complete response". This SNP was one of the top 10 SNPs to show association with response to bevacizumab, but did not remain associated after multiple testing correction. Allele C is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele G. 26100253 1447813757
VEGFA rs3025039 T anthracyclines and related substances efficacy no Patients were women with HER2- breast cancer. SNPs in genes in the VEGF pathway were selected to be genotyped (170 plus 16 that were previously investigated for association with response to bevacizumab) and compared between women who received bevacizumab and women who did not. The response was "pathological complete response". This SNP was one of the top 10 SNPs to show association with response to bevacizumab, but did not remain associated after multiple testing correction. Allele T is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele C. 26100253 1447813751
VEGFA rs2010963 CC + CG enalapril efficacy no Hypertensive patients were administered either 10 mg/day (n = 48) or 20 mg/day (n = 54) of enalapril, based on physician's judgment (who took risk factors and previous history of treatment into account). Genotypes CC + CG are not associated with response to enalapril in people with Hypertension as compared to genotype GG. 26002049 1446900422
VEGFA rs1570360 AG + GG enalapril efficacy no Hypertensive patients were administered either 10 mg/day (n = 48) or 20 mg/day (n = 54) of enalapril, based on physician's judgment (who took risk factors and previous history of treatment into account). Genotypes AG + GG are not associated with response to enalapril in people with Hypertension as compared to genotype AA. 26002049 1446900410
VEGFA rs25648 T adalimumab efficacy yes Allele T is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele C. 28639493 1448633699
VEGFA rs833061 T pazopanib efficacy yes Allele T is associated with decreased response to pazopanib in people with Carcinoma, Renal Cell as compared to allele C. 21576632 1448568024
VEGFA rs2010963 G pazopanib efficacy yes Allele G is associated with decreased response to pazopanib in people with Carcinoma, Renal Cell as compared to allele C. 21576632 1448568038
VEGFA rs3025039 C lenalidomide efficacy no Allele C is not associated with decreased response to lenalidomide or thalidomide in people with Multiple Myeloma as compared to allele T. 28373444 1448612688
VEGFA rs833061 CT + TT carfilzomib efficacy yes Authors indicate repose as CR/nCR/sCR but do not define these and non-response as VGPR and PR/SD (which assume to mean progression/stable disease). They also test "minimum residual disease negativity" MRD- as measure of response. Genotypes CT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC. 28488026 1448634646
VEGFA rs2010963 C imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G. 30713339 1450933537
VEGFA rs3025039 T imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C. 30713339 1450933553
VEGFA rs833061 T imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C. 30713339 1450933569
VEGFA rs699947 C imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A. 30713339 1450933561
VEGFA rs25648 CT + TT cisplatin efficacy yes Partial remissions and disease control rate was higher in patients with the CC genotype (p=0.04 and p=0.002, respectively), progression-free survival and overall survival were also higher in patients with the CC genotype. Genotypes CT + TT are associated with decreased response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CC. 24090479 1183700819
VEGFA rs699946 A ranibizumab efficacy no Patients underwent 5 monthly injections. Good response at month 5 was defined as best-corrected visual acuity improvement of >= 8 Early Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline. Bonferroni correction for multiple testing. Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G. 23842101 1184510434
VEGFA rs699947 AC capecitabine efficacy yes The aim of this study was to investigate the possible predictive value of the VEGF-A SNPs, in patients with metastatic colorectal cancer (mCRC) treated with first-line capecitabine and oxaliplatin (XELOX). Response was observed in 21% of the patients with the -2578 (rs699947) CA genotype compared with 59% of the patients with CC + AA, P = 0.002, in 26% of the patients with the -460 (rs833061) CT genotype compared with 57% with CC = TT, P = 0.01, and in 27% of the patients with the 405 (rs2010963) GC genotype compared with 54% with GG + CC, P = 0.02. Genotype AC is associated with decreased response to capecitabine and oxaliplatin in people with Colorectal Neoplasms. 20125120 769250751
VEGFA rs699947 AC ranibizumab efficacy no Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections. Genotype AC is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype CC. 22840423 981755243
VEGFA rs25648 T imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C. 30713339 1450933545
VEGFA rs699947 AA ranibizumab efficacy no Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections. Genotype AA is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype CC. 22840423 981755237
VEGFA rs699947 AA + AC sildenafil efficacy yes Heterozygote was only significant in the clinical subgroup not the postoperative subgroup. (OR below are for the homozygotes but for the clinical subgroup OR for the heterozygote was 2.01 (1.08-3.74)) Genotypes AA + AC are associated with decreased response to sildenafil in men with Erectile Dysfunction as compared to genotype CC. 23007311 981349362
VEGFA rs699947 AC + CC ranibizumab efficacy yes Those with the AA genotype had an absence of early functional response to treatment. Response was measured by difference of best corrected visual acuity (ETDRS letters) pre- and post- treatment. Genotypes AC + CC are associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype AA. 23570466 982025943
VEGFA rs699947 CC bevacizumab efficacy no No significant difference in genotype frequencies was seen between patients classified as non-responders, and those classified as responders or partial responders. Responder status was determined by optical coherence tomography; please refer to the paper directly for definitions of responder, partial responder, and non-responder. Genotype CC is not associated with response to bevacizumab in people with Macular Degeneration as compared to genotypes AA + AC. 23584701 1184166157
VEGFA rs699947 A ranibizumab efficacy no Patients underwent 5 monthly injections. Good response at month 5 was defined as best-corrected visual acuity improvement of >= 8 Early Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline. Bonferroni correction for multiple testing. Note that the uncorrected p-value was significant for this allele (p=0.0072), where patients with the AA genotype had a increased chance at a good response, as compared to those with the AG or GG genotype. This result was also significant in multivariate analysis (p=0.0071). Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele C. 23842101 1184510438
VEGFA rs699947 CC bevacizumab efficacy yes Response to treatment was determined by RECIST criteria. Genotype CC is associated with increased response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AC. 25955730 1444842390
VEGFA rs699947 AA + AC enalapril efficacy yes Hypertensive patients were administered either 10 mg/day (n = 48) or 20 mg/day (n = 54) of enalapril, based on physician's judgment (who took risk factors and previous history of treatment into account). It was only in the patients taking 20 mg/day that results for the AA and AC genotypes was significantly associated with a decrease in mean blood pressure (but not systolic, or diastolic blood pressure). The A allele was also associated with improved response to 20 mg/day of enalapril when part of a haplotype with rs1570360 and rs2010963 (VEGFA H3). Genotypes AA + AC are associated with increased response to enalapril in people with Hypertension as compared to genotype CC. 26002049 1446900395
VEGFA rs699947 C anthracyclines and related substances efficacy no Patients were women with HER2- breast cancer. SNPs in genes in the VEGF pathway were selected to be genotyped (170 plus 16 that were previously investigated for association with response to bevacizumab) and compared between women who received bevacizumab and women who did not. The response was "pathological complete response". This SNP was one of the top 10 SNPs to show association with response to bevacizumab, but did not remain associated after multiple testing correction. Allele C is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele A. 26100253 1447813745
VEGFA rs699947 A pazopanib efficacy yes Allele A is associated with decreased response to pazopanib in people with Carcinoma, Renal Cell as compared to allele C. 21576632 1448568032
VEGFA rs833061 CT capecitabine efficacy no The aim of this study was to investigate the possible predictive value of the VEGF-A SNPs, in patients with metastatic colorectal cancer (mCRC) treated with first-line capecitabine and oxaliplatin (XELOX). Response was observed in 21% of the patients with the -2578 (rs699947) CA genotype compared with 59% of the patients with CC + AA, P = 0.002, in 26% of the patients with the -460 (rs833061) CT genotype compared with 57% with CC = TT, P = 0.01, and in 27% of the patients with the 405 (rs2010963) GC genotype compared with 54% with GG + CC, P = 0.02. Genotype CT is not associated with response to capecitabine and oxaliplatin in people with Colorectal Neoplasms. 20125120 769250837
VEGFA rs833061 CC + CT cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes CC + CT are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype TT. 24090479 1183700971
VEGFA rs833061 C bevacizumab efficacy no Response was determined by RECIST criteria. In a subgroup analysis excluding the use of anti-angiogenic agents (e.g. bevacuzimab) no significant association was found for any genotypes and response to chemotherapy. Allele C is not associated with response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele T. 25955730 1444842405
VEGFA rs833061 TT cetuximab efficacy yes Genotype TT is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes CC + CT. 26615857 1447674843
VEGFA rs833069 C ranibizumab efficacy no Age-related macular degeneration. No significant differences in best-corrected visual acuity (BCVA) changes were seen between baseline and 3 or 6 months of treatment between any of the genotypes. Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T. 23559864 1183682066
VEGFA rs833069 CC + CT ranibizumab efficacy yes Age-related macular degeneration. Patients with the CC or CT genotype had greater decreases in central subfield macular thickness (CSMT) between baseline and 3 or 6 months of treatment, as compared to those with the TT genotype. This indicates a better visual outcome. Please note alleles have been complemented to the plus chromosomal strand. Genotypes CC + CT are associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype TT. 23559864 1183682073
VEGFA rs833069 C bevacizumab efficacy no Please note that alleles have been complemented to the positive strand. Allele C is not associated with response to bevacizumab in women with Breast Neoplasms as compared to allele T. 28045923 1448995836
VEGFA rs1570360 GG bevacizumab efficacy yes rs number not given in this paper. Found rs number for VEGF -1154 in PMID:17204151 Genotype GG is associated with decreased response to bevacizumab and irinotecan in people with Colorectal Neoplasms as compared to genotypes AA + AG. 21844885 827707457
VEGFA rs1570360 AA sildenafil efficacy yes Genotype AA is associated with decreased response to sildenafil in men with Erectile Dysfunction as compared to genotypes AG + GG. 23007311 981349353
VEGFA rs2010963 CG capecitabine efficacy yes The aim of this study was to investigate the possible predictive value of the VEGF-A SNPs, in patients with metastatic colorectal cancer (mCRC) treated with first-line capecitabine and oxaliplatin (XELOX). Response was observed in 21% of the patients with the -2578 (rs699947) CA genotype compared with 59% of the patients with CC + AA, P = 0.002, in 26% of the patients with the -460 (rs833061) CT genotype compared with 57% with CC = TT, P = 0.01, and in 27% of the patients with the 405 (rs2010963) GC genotype compared with 54% with GG + CC, P = 0.02. Genotype CG is associated with decreased response to capecitabine and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + GG. 20125120 769250871
VEGFA rs2010963 CC + CG cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes CC + CG are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype GG. 24090479 1183700959
VEGFA rs2010963 CC bevacizumab efficacy yes A lower percentage of patients with the CC genotype maintained visual acuity 1 year after the first anti-VEGF injection, as compared to those with the CG or GG genotype (Cochran-Armitage test). Additionally, multivariable logistic regression showed that the G allele was associated with an increased likelihood of maintaining visual acuity 1 year after the first injection both in all patients (n=83), and in patients who had their eyes treated with only a single initial treatment (n=65). Visual acuity was measured by the Landolt chart. Anti-VEGF treatments included bevacizumab (n=62), pegaptanib (n=3) or ranibizumab (n=18). Genotype CC is associated with decreased response to bevacizumab, pegaptanib or ranibizumab in people with Choroidal Neovascularization as compared to genotypes CG + GG. 23953100 1184168589
VEGFA rs2146323 CC bevacizumab efficacy no No significant difference in genotype frequencies was seen between patients classified as non-responders, and those classified as responders or partial responders. Responder status was determined by optical coherence tomography; please refer to the paper directly for definitions of responder, partial responder, and non-responder. Genotype CC is not associated with response to bevacizumab in people with Macular Degeneration as compared to genotypes AA + AC. 23584701 1184166162
VEGFA rs3025039 CT + TT cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes CT + TT are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CC. 24090479 1183700964
VEGFA rs3025000 CT + TT bevacizumab efficacy yes Response was measured by mean change in visual acuity from baseline after 3, 6 and 12 months of treatment. Visual acuity was scored using Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Patients were segregated into responders (gain of > or = 5 ETDRS letters), stable (gain or loss of < 5 ETDRS letters), or nonresponders (loss of > 5 ETDRS letters. Carriers of the T allele were more likely to be in the responders group than in the stable or nonresponders group after 3, 6 and 12 months of treatment. Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC. 23149126 981793920
VEGFA rs3025000 CT + TT bevacizumab efficacy yes Response was measured by mean change in visual acuity from baseline after 3, 6 and 12 months of treatment. Visual acuity was scored using Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Carriers of the T allele had a significantly greater increase in visual outcome after 6 months of treatment, as compared to the CC genotype. No significant change was seen after 3 or 12 months of treatment after Bonferroni correction was used, which set the p-value at <0.007. Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC. 23149126 981793872
VEGFA rs3025033 G anthracyclines and related substances efficacy no Patients were women with HER2- breast cancer. SNPs in genes in the VEGF pathway were selected to be genotyped (170 plus 16 that were previously investigated for association with response to bevacizumab) and compared between women who received bevacizumab and women who did not. The response was "pathological complete response". This SNP was one of the top 10 SNPs to show association with response to bevacizumab, but did not remain associated after multiple testing correction. Allele G is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele A. 26100253 1447813823
VEGFA rs3025039 T cetuximab efficacy no Meta-analysis with 3 studies. The authors did not provide the exact number of patients but stated that "the median number of patients per analysis was 110 (range 50 - 740)". Most definitions of response were variations of the RECIST criteria. Allele T is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele C. 27897268 1449165400